Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/452313


Menarini: PharmaVitae Profile


Description: This analysis examines the historical and forecast performance for Menarini in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope



Highlights of this title



Key reasons to purchase this title


- Benchmark Menarinis performance against key rivals in the ethical pharmaceutical sector

- See how Menarini will achieve relatively low growth as the small gains made by some products are counteracted by the small losses felt by others

- Learn how despite the launch of its first major internally discovered product, amediplase, the company will remain heavily reliant on externalization


Contents: CHAPTER 1 EXECUTIVE SUMMARY 2
Key findings 2
Historical and forecast ethical sales performance 3
Therapeutic strategy 4
Launch and expiry outlook 6
Externalization, geographic and molecule type strategies 8
Externalization strategy 9
Geographic strategy 10
Molecule type strategy 10
SWOT analysis 11
Strengths 11
Weaknesses 11
Opportunities 12
Threats 12
CHAPTER 2 CORPORATE HISTORY 16
Key findings 16
Background 17
Key corporate developments 17
M&A history 18
M&A strategy 18
Current corporate structure 19
Menarini Research 19
Menarini Diagnostics 19
Menarini OTC Division 20
Menarini Biotech 20
Current management team 20
CHAPTER 3 HISTORICAL PERFORMANCE 21
Key findings 21
Introduction 22
Turnover and growth rate analysis, 2001-06 22
Revenue and growth rate vs. peer set 23
Product analysis, 2001-06 25
Operating revenue and cost analysis, 2001-06 25
CHAPTER 4 FORECAST PERFORMANCE 26
Key findings 26
Introduction 27
Revenue and growth rate, 2006-12 27
Product analysis, 2006-12 28
Growth drivers 31
Votum 31
Nebilet 32
Berlinsulin H 32
Growth resistors 32
Other CV 32
Aliflus Diskus 32
Macladin 32
Therapy area analysis, 2006-12 34
Cardiovascular & hematology 36
Endocrine, metabolic & genetic disorders 36
Respiratory 37
Therapy area focus 37
Launches and expiries analysis, 2006-12 40
Launch portfolio 40
Core portfolio 42
Expiry portfolio 44
Launch/core/expiry configuration 46
Externalization analysis, 2006-12 48
Geographic analysis, 2006-12 54
Molecule type analysis, 2006-12 58
CHAPTER 5 KEY PRODUCTS AND COMPETITORS 63
Key findings 63
Overview 64
Cardiovascular 65
Votum 65
Overview 65
Sales forecast 66
Newsflow 66
Competitive landscape 66
Nebilet 68
Overview 68
Sales forecast 69
Newsflow 69
Competitive landscape 69
Totalip 71
Overview 71
Sales forecast 72
Newsflow 72
Competitive landscape 73
Respiratory 74
Aliflus Diskus 74
Overview 74
Sales forecast 75
Newsflow 75
Competitive landscape 75
Infectious disease 78
Macladin 78
Overview 78
Sales forecast 79
Newsflow 79
Competitive landscape 79
Gastrointestinal 81
Lucen 81
Overview 81
Sales forecast 82
Newsflow 82
Competitive landscape 82
CHAPTER 6 APPENDIX 84
IMS vs. company-reported data reconciliation 84
Abbreviations 86
Exchange rates 87
List of Tables
Table 1: Menarini Group management team 20
Table 2: Peer set overview 23
Table 3: Product portfolio overview, sales ($m), 2006-12 28
Table 4: Therapy area overview, sales ($m), 2006-12 34
Table 5: Launch portfolio overview, sales ($m), 2006-12 40
Table 6: Core portfolio overview, sales ($m), 2006-12 42
Table 7: Expiry portfolio overview, sales ($m), 2006-12 44
Table 8: Externally developed portfolio ($m), 2006-12 49
Table 9: Molecule type overview, sales ($m), 2006-12 58
Table 10: Key products overview 64
Table 11: Votum: overview 65
Table 12: Votum: sales forecast ($m), 2006-12 66
Table 13: Nebilet: overview 68
Table 14: Nebilet: sales forecast ($m), 2006-12 69
Table 15: Totalip: overview 71
Table 16: Totalip: sales forecast ($m), 2006-12 72
Table 17: Totalip: newsflow 72
Table 18: Aliflus Diskus: overview 74
Table 19: Aliflus Diskus: sales forecast ($m), 2006-12 75
Table 20: Macladin: overview 78
Table 21: Macladin: sales forecast ($m), 2006-12 79
Table 22: Lucen: overview 81
Table 23: Lucen: sales forecast ($m), 2006-12 82
Table 24: Exchange rates, 2006 87
List of Figures
Figure 1: Historical and forecast ethical sales performance (% CAGR), Menarini and Mid Pharma peer set 3
Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2006 5
Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Menarini 6
Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 7
Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006 8
Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012 9
Figure 7: SWOT analysis of Menarini 11
Figure 8: M&A/divestment history 18
Figure 9: Current corporate structure 19
Figure 10: Revenue & growth rate (ethical sales) ($m), 2001-06 22
Figure 11: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06 24
Figure 12: Ethical revenue ($m) and growth rate (%), 2006-12 27
Figure 13: Top five products by sales ($m), 2006 29
Figure 14: Top five products by sales ($m), 2012 30
Figure 15: Growth drivers and resistors by product, 2006-12 31
Figure 16: Key strategic products, sales ($m), 2006-12 33
Figure 17: Ethical sales by therapy area ($m), 2006-12 35
Figure 18: Growth drivers and resistors by therapy area ($m), 2006-12 36
Figure 19: Ethical sales by therapy area (%), 2006-12 37
Figure 20: Therapy area focus compared with peer set (% total ethical sales), 2006 38
Figure 21: Therapy area focus compared with peer set (% total ethical sales), 2012 39
Figure 22: Launch schedule, sales ($m), 2006-12 41
Figure 23: Core products sales growth ($m), 2006-12 43
Figure 24: Expiry schedule, sales ($m), 2006-12 45
Figure 25: Launch, core and expiry, sales ($m), 2006-12 46
Figure 26: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Menarini 47
Figure 27: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 48
Figure 28: Externalization dependency, sales ($m), 2006-12 50
Figure 29: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12 51
Figure 30: Externalization dependency vs. peer set, % total sales, 2006 52
Figure 31: Externalization dependency vs. peer set, % total sales, 2012 53
Figure 32: Geographical sales breakdown ($m), 2006-12 54
Figure 33: Growth drivers and resistors by geography, sales ($m), 2006-12 55
Figure 34: US dependency vs. peer set, % total sales, 2006 56
Figure 35: US dependency vs. peer set, % total sales, 2012 57
Figure 36: Growth drivers and resistors by molecule type, sales ($m), 2006-12 59
Figure 37: Molecule type sales breakdown ($m), 2006-12 60
Figure 38: Biologics dependency vs. peer set, % total sales, 2006 61
Figure 39: Biologics dependency vs. peer set, % total sales, 2012 62
Figure 40: IMS vs. company-reported ethical sales discrepancy ($m), 2006 85
Figure 41: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12 86


Companies Mentioned Abbott Laboratories AstraZeneca PLC Bristol-Myers Squibb Company Daiichi Sankyo, Ltd. GlaxoSmithKline Plc IMS Health Johnson & Johnson Merck & Co., Inc. Novartis AG Novo Nordisk A/S Pfizer Inc Servier Taisho Pharmaceutical Co., Ltd.


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/452313

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 16/10/2008 05:51:31
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Menarini: PharmaVitae Profile
Web Address:
http://www.researchandmarkets.com/reports/452313
Office Code:
OCHKIKMORSZ

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Hard Copy €6,195.00 + EUR€ 50.00 Shipping/Handling *
Electronic (PDF) - Single User €6,099.00

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 16/10/2008 05:51:31

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World